DG1 Spectacle Lens for Myopia Progression Control in Children
NCT ID: NCT06781931
Last Updated: 2025-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
240 participants
INTERVENTIONAL
2025-01-21
2030-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To assess if the DG1 lens will slow the progression of myopia through an adjusted mean difference (e.g., age and baseline SER) of approximately 0.75D in cycloplegic spherical equivalent autorefraction refractive error compared to single-vision (SV) spectacles over the study period.
* To assess if DG1 lens will slow the progression of myopia through an adjusted mean difference (e.g., age and baseline SER) of approximately 0.3mm in axial elongation compared to SV over the study period.
The clinical trial will compare DG1 spectacle lens to single vision spectacle lens.
Participants will wear spectacle lenses and return for visits at regularly scheduled intervals through a 36-month follow up visit. All subjects who complete the 36-month visit will continue in the study for an additional 12 months for the rebound evaluation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Myopia Control Efficacy of Second-generation DIMS Spectacle Lenses on Fast Progressing Myopes
NCT05888792
Control of Myopia Using Novel Spectacle Lens Designs
NCT03623074
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
NCT06034327
Early Intervention for Premyopic Children
NCT06200194
Light Diffraction Glasses in Preventing and Controlling Myopia in Adolescents
NCT06927414
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DG1 Spectacle Lens
DG1 Spectacle Lens
DG1 spectacle lens, daily wear for 36 months
Single Vision Spectacle Lens
Single Vision Spectacle Lens
Single vision spectacle lens, daily wear for 36 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DG1 Spectacle Lens
DG1 spectacle lens, daily wear for 36 months
Single Vision Spectacle Lens
Single vision spectacle lens, daily wear for 36 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The subject and parent (or guardian) must attend required study visits and adhere to study requirements.
3. Parent (or guardian) understands and accepts random allocation of grouping, and that subject and parent (or guardian) will not be told the group which the subject is randomized to.
4. The subject is able and willing to wear provided frames and lenses (spectacles), for an average of 10 hours per day for the entirety of the study.
5. Age of subject at time of parent (or guardian) consent and subject assent: 7 to 10 years old (inclusive).
6. Cycloplegic autorefraction spherical equivalent refraction (SER): -1.00 to -5.00 D in each eye at the screening visit.
7. Cycloplegic autorefraction astigmatism of 1.50 D or less in each eye at the screening visit.
8. Cycloplegic spherical equivalent autorefraction (SER) anisometropia of 1.50 D or less at the screening visit.
9. Monocular cycloplegic best corrected distance visual acuity (BCDVA) equal to or better than log MAR 0.10 in each eye at the screening visit.
Exclusion Criteria
2. Subjects with ocular or systemic abnormalities that might be expected to affect visual functions or refractive development.
3. Subjects who have received treatment of myopia control pharmaceutical medication (e.g., atropine), myopia control contact lenses, other myopia control spectacles, orthokeratology lenses, progressive addition lenses, bifocal lenses, or single vision contact lens prior to entry into the study or during the duration of the study.
4. Subjects with, or a medical history of, strabismus.
5. Subjects with a medical history of binocular vision abnormalities or accommodation abnormalities based on the opinion of the investigator.
6. Subjects with, or history of, amblyopia.
7. Subjects who have participated in a clinical trial within 30 days prior to entry into this study or during participation.
8. Subjects with a history of intraocular surgery.
9. Subjects who, in the judgment of the investigator, have any emotional, physiologic, or anatomical condition which may preclude participation in this study or provide an inappropriate landscape for the intended study treatment.
10. Subjects with pathological myopia (myopia that leads to structural changes in the posterior segment of the eye including posterior staphyloma, myopic maculopathy, and high myopia-associated optic neuropathy).
11. Individuals from the same household (i.e., siblings), employees (or family members of employees) of the Principal Investigator/site, employees (or family members of employees) of the Sponsor, and non-readers.
7 Years
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HOYA Lens Thailand LTD.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Irvine Vision Center
Irvine, California, United States
Columbia Eye Associates & Family Focus Eye Care
Gainesville, Florida, United States
Coan Eye Care and Optical Boutique
Ocoee, Florida, United States
Illinois College of Optometry
Chicago, Illinois, United States
Complete Eye Care of Medina
Medina, Minnesota, United States
Oculus Research, Inc.
Garner, North Carolina, United States
ProCare Vision Centers, Inc.
Granville, Ohio, United States
EyeCare Professionals of Powell
Powell, Ohio, United States
Southern College of Optometry
Memphis, Tennessee, United States
Virginia Pediatric Eye Center
Virginia Beach, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DG1-101-KIND
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.